Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy
about
A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injuryAcute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity.An international consensus approach to the management of atypical hemolytic uremic syndrome in children.ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.Genetic variations in complement factors in patients with congenital thrombotic thrombocytopenic purpura with renal insufficiency.Thrombotic Thrombocytopenic Purpura: Pathogenesis, Diagnosis, and Potential Novel Therapeutics.von Willebrand factor is a cofactor in complement regulation.Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli - An Anti-thrombotic Mechanism in the Kidney.Reincarnation of ancient links between coagulation and complement.Extracellular vesicles in renal disease.Early Terminal Complement Blockade and C6 Deficiency Are Protective in Enterohemorrhagic Escherichia coli-Infected Mice.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis.Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases.The role of von Willebrand factor in thrombotic microangiopathy.C1-Inhibitor Decreases the Release of Vasculitis-Like Chemotactic Endothelial Microvesicles.Plasma ADAMTS-13 activity in proliferative lupus nephritis: a large cohort study from China.Acquired thrombotic thrombocytopenic purpura with isolated CFHR3/1 deletion-rapid remission following complement blockade.
P2860
Q26992169-41F6041E-1289-4F25-ACE4-4D42F1234984Q33419414-E2A9A41C-A452-4590-B1DA-9B0AB7D8DF4AQ33421861-7CC29C33-52A4-4E56-ABA9-747BD6E44960Q33427651-0C990CA3-AA21-45CB-8940-2085A70C7C33Q33429667-21E703FC-B0BF-44C5-AE68-E10B060B0385Q33443111-D422A312-B3E5-449F-A06F-9FE1C9422042Q35056291-4E662160-5DCB-4162-8FD6-CC6A4A718153Q36264512-007BDF55-7316-47DF-B946-525276602441Q38543278-354F2127-E9A1-404F-B3FC-CA1EA58ADB2EQ39453434-027EBE2F-72C6-4A2E-872F-3C1C90E76B18Q40612027-0F5C04DC-C15A-4CC3-A95A-11D535243C9DQ42086661-38EB1867-647C-4E69-9E69-ADB158199C09Q47599879-F569C8A7-AA41-4FDC-801E-05B3DACF1542Q48220242-4F03413A-FFF5-41E9-8FF2-6CF035B8D434Q48225900-9F94485D-2EC3-4F04-8A8D-B8EEE78B1DE4Q48338971-8F506701-71C5-4A81-9BC0-B8D84BA1D916Q51100129-CA8011A2-B12F-414B-8370-223A4E6BC4AEQ52759733-0FC4690C-7BC2-40F8-9E28-2583107FD6E6Q53819914-19ECE442-A3F6-4429-8673-665086716E73
P2860
Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Complement activation associat ...... ine thrombotic microangiopathy
@ast
Complement activation associat ...... ine thrombotic microangiopathy
@en
type
label
Complement activation associat ...... ine thrombotic microangiopathy
@ast
Complement activation associat ...... ine thrombotic microangiopathy
@en
prefLabel
Complement activation associat ...... ine thrombotic microangiopathy
@ast
Complement activation associat ...... ine thrombotic microangiopathy
@en
P2093
P2860
P356
P1476
Complement activation associat ...... ine thrombotic microangiopathy
@en
P2093
Ann-Charlotte Kristoffersson
Anne-Lie Ståhl
Christoph Licht
David Motto
Ramesh Tati
P2860
P304
P356
10.4049/JIMMUNOL.1301221
P407
P577
2013-07-22T00:00:00Z